Literature DB >> 20605289

Bisphosphonate osteonecrosis of the jaw--a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention.

Vinod Patel1, Niall M H McLeod, Simon N Rogers, Peter A Brennan.   

Abstract

There has been an exponential rise in the literature of osteonecrosis and its complications in patients taking bisphosphonate drugs. Despite this increase, there is little evidence-based publications on how best to manage this complication. In this article (the first of two on bisphosphonate related jaw complications), we compare the guidelines produced by national specialist medical associations and expert panels on the prevention of bisphosphonate osteonecrosis of the jaws and review the evidence behind these guidelines.
Copyright © 2010 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605289     DOI: 10.1016/j.bjoms.2010.05.007

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  17 in total

1.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

Review 2.  Pre- and postoperative management techniques. Before and after. Part 1: medical morbidities.

Authors:  J Mansoor
Journal:  Br Dent J       Date:  2015-03-13       Impact factor: 1.626

3.  An in vitro assessment of fibroblast and osteoblast response to alendronate-modified titanium and the potential for decreasing fibrous encapsulation.

Authors:  Xuefeng Hu; Koon Gee Neoh; Zhilong Shi; En-Tang Kang; Wilson Wang
Journal:  Tissue Eng Part A       Date:  2013-04-26       Impact factor: 3.845

4.  Effects of pamidronate on human alveolar osteoblasts in vitro.

Authors:  Darja Marolt; Matthew Cozin; Gordana Vunjak-Novakovic; Serge Cremers; Regina Landesberg
Journal:  J Oral Maxillofac Surg       Date:  2012-05       Impact factor: 1.895

Review 5.  Potential pathophysiological mechanisms in osteonecrosis of the jaw.

Authors:  Regina Landesberg; Victoria Woo; Serge Cremers; Matthew Cozin; Darja Marolt; Gordana Vunjak-Novakovic; Stavroula Kousteni; Srikala Raghavan
Journal:  Ann N Y Acad Sci       Date:  2011-02       Impact factor: 5.691

Review 6.  Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.

Authors:  Mohamed E Awad; Christina Sun; Joshua Jernigan; Mohammed Elsalanty
Journal:  J Am Dent Assoc       Date:  2019-06-28       Impact factor: 3.634

7.  Platelet-rich growth factor in oral and maxillofacial surgery.

Authors:  Uma Shanker Pal; Shadab Mohammad; Rakesh K Singh; Somdipto Das; Nimisha Singh; Mayank Singh
Journal:  Natl J Maxillofac Surg       Date:  2012-07

Review 8.  Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.

Authors:  Kyoung Min Kim; Yumie Rhee; Yong-Dae Kwon; Tae-Geon Kwon; Jeong Keun Lee; Deog-Yoon Kim
Journal:  J Bone Metab       Date:  2015-11-30

9.  Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients.

Authors:  Pelagia I Melea; Ioannis Melakopoulos; Efstathios Kastritis; Christina Tesseromatis; Vasileios Margaritis; Meletios A Dimopoulos; Evangelos Terpos
Journal:  Int J Dent       Date:  2014-06-17

10.  Risk factors and indices of osteomyelitis of the jaw in osteoporosis patients: results from a hospital-based cohort study in Japan.

Authors:  Toru Yamazaki; Masashi Yamori; Shiro Tanaka; Keiichi Yamamoto; Eriko Sumi; Megumi Nishimoto-Sano; Keita Asai; Katsu Takahashi; Takeo Nakayama; Kazuhisa Bessho
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.